Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22367073 | 1.00 | NPSR1 (0.47) | NPSR1TRPC6MAPK1GAAKDM4E | |
| SCHEMBL30506270 | 0.81 | NPSR1 (0.44) | NPSR1TRPC6MAPK1SMN1; SMN2PDE4A | |
| SCHEMBL1425473 | 0.80 | RECQL (0.41) | NPSR1GAASMN1; SMN2PDE4APDE4B | |
| SCHEMBL21045701 | 0.76 | TSHR (0.55) | TRPC6MAPK1KDM4EMAPTTSHR | |
| SCHEMBL21045659 | 0.75 | TRPC6 (0.48) | NPSR1TRPC6MAPK1KDM4EMAPT | |
| SCHEMBL20116265 | 0.74 | MAPK1 (0.68) | MAPK1GAAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL29040322 | 0.74 | MAPK1 (0.68) | MAPK1GAAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL29040358 | 0.73 | TRPC6 (0.46) | TRPC6MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL20116727 | 0.72 | NPSR1 (0.40) | NPSR1MAPK1GAAKDM4EMAPT | |
| SCHEMBL20116736 | 0.72 | GAA (0.44) | NPSR1MAPK1GAAMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| EP-3700934-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NPSR1 386/4885TRPC6 914/4885MAPK1 4304/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NPSR1 386/4885TRPC6 914/4885MAPK1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.